National Pension Service lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 5.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 233,062 shares of the biotechnology company’s stock after acquiring an additional 12,168 shares during the period. National Pension Service owned 0.13% of BioMarin Pharmaceutical worth $15,708,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Nuveen Asset Management LLC acquired a new position in BioMarin Pharmaceutical in the 2nd quarter valued at about $258,055,000. York Capital Management Global Advisors LLC purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth about $95,648,000. DekaBank Deutsche Girozentrale grew its holdings in shares of BioMarin Pharmaceutical by 454.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 458,424 shares of the biotechnology company’s stock worth $38,584,000 after buying an additional 375,760 shares in the last quarter. Marshall Wace LLP raised its position in shares of BioMarin Pharmaceutical by 59,167.2% in the second quarter. Marshall Wace LLP now owns 282,112 shares of the biotechnology company’s stock valued at $24,162,000 after buying an additional 281,636 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $21,553,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently issued reports on BMRN. William Blair restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Friday, November 15th. Barclays raised shares of BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $86.00 to $98.00 in a research note on Wednesday, November 27th. Piper Jaffray Companies set a $120.00 price target on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Friday, September 13th. Stifel Nicolaus set a $108.00 price target on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, SunTrust Banks began coverage on BioMarin Pharmaceutical in a report on Tuesday, November 12th. They set a “buy” rating and a $110.00 price objective on the stock. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $107.67.
Shares of BMRN opened at $79.86 on Tuesday. The firm has a market cap of $14.50 billion, a PE ratio of -242.00, a price-to-earnings-growth ratio of 125.07 and a beta of 1.31. The company’s fifty day moving average is $74.20 and its two-hundred day moving average is $77.49. BioMarin Pharmaceutical Inc. has a fifty-two week low of $62.88 and a fifty-two week high of $100.13. The company has a quick ratio of 2.53, a current ratio of 3.77 and a debt-to-equity ratio of 0.27.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.25. The business had revenue of $461.10 million during the quarter, compared to the consensus estimate of $455.78 million. BioMarin Pharmaceutical had a negative return on equity of 1.35% and a negative net margin of 2.65%. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.07) EPS. As a group, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.01 earnings per share for the current year.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Article: What does it mean to hold a stock in street name?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.